{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:20:00Z","timestamp":1787545200184,"version":"build-2736575974"},"reference-count":34,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258519"],"award-info":[{"award-number":["R01CA258519"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"award":["R01CA258519"],"award-info":[{"award-number":["R01CA258519"]}],"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background and Clincal significance: Esophageal squamous cell carcinoma (ESCC) classically presents with progressive dysphagia and weight loss, but atypical presentations may redirect the diagnostic workup before the esophageal primary is identified. We report a case illustrating the simultaneous convergence of three diagnostic pitfalls: absence of dysphagia, bone-predominant metastatic presentation initially managed as carcinoma of unknown primary (CUP), and negative p40 staining in a vertebral biopsy in a patient subsequently confirmed to have invasive mid-esophageal squamous cell carcinoma. CasePresentation: A 66-year-old African American man with dementia, active tobacco exposure, and prior alcohol use disorder presented with constipation, abdominal pain, melena, fever, nausea, vomiting, and progressive back pain. Dysphagia or odynophagia was not documented. CT of the abdomen and pelvis demonstrated diffuse lytic osseous metastases. During evaluation and palliation of symptomatic L2 disease, kyphoplasty and radiofrequency ablation were performed, and bilateral core biopsies showed poorly differentiated carcinoma that was AE1\/AE3-positive but negative for p40, CK7, CK20, TTF-1, S100, GATA-3, PAX8, and NKX3.1, yielding an initial diagnosis of CUP. Subsequent chest CT revealed esophageal wall thickening with intraluminal debris. Esophagogastroduodenoscopy (EGD) identified a non-obstructive ulcerated mid-esophageal lesion, and biopsy confirmed invasive squamous cell carcinoma. Poor performance status precluded systemic therapy; palliative external-beam radiation was initiated after diagnosis but discontinued because of clinical deterioration, and the patient transitioned to hospice before passing several weeks after diagnosis. Melena is a gastrointestinal alarm feature, and the combination of gastrointestinal bleeding and an esophageal imaging abnormality warrants timely endoscopic evaluation even when dysphagia is not reported or the symptom history is unreliable. Negative p40 staining in a poorly differentiated, potentially decalcified bone specimen may reflect loss of lineage-marker expression, technical antigen degradation, or both. Tissue or plasma genomic profiling and emerging cell-free DNA methylation classifiers could complement the workup but would not replace direct biopsy of a radiographically suspicious esophageal lesion. Conclusions: In metastatic poorly differentiated carcinoma, lack of documented dysphagia should not exclude an esophageal primary, particularly in patients with cognitive impairment. A p40-negative bone biopsy does not rule out squamous lineage. Timely EGD and integrated clinicopathologic assessment are essential when clinical or imaging findings suggest esophageal involvement.<\/jats:p>","DOI":"10.3390\/diagnostics16162677","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:51:05Z","timestamp":1787327465000},"page":"2677","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Occult Esophageal Squamous Cell Carcinoma Presenting as Bone-Predominant Carcinoma of Unknown Primary: A Case Report of a p40-Negative Vertebral Metastasis"],"prefix":"10.3390","volume":"16","author":[{"given":"Hassan","family":"Brim","sequence":"first","affiliation":[{"name":"Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington, DC 20060, USA"},{"name":"Department of Pathology, Howard University, Washington, DC 20060, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wardah","family":"Bajwa","sequence":"additional","affiliation":[{"name":"Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington, DC 20060, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Brim","sequence":"additional","affiliation":[{"name":"Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington, DC 20060, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad","family":"Aduli","sequence":"additional","affiliation":[{"name":"Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington, DC 20060, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"AbdelLatief","sequence":"additional","affiliation":[{"name":"Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington, DC 20060, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Zafar","sequence":"additional","affiliation":[{"name":"Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington, DC 20060, USA"},{"name":"Department of Pathology, Howard University, Washington, DC 20060, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeyinka O.","family":"Laiyemo","sequence":"additional","affiliation":[{"name":"Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington, DC 20060, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4048-4666","authenticated-orcid":false,"given":"Hassan","family":"Ashktorab","sequence":"additional","affiliation":[{"name":"Department of Medicine, GI Division, Cancer Center, Howard University Hospital, Washington, DC 20060, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"ref_1","unstructured":"National Comprehensive Cancer Network (2026, June 02). NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. Version 2. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1433."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040","volume":"163","author":"Morgan","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.asjsur.2016.10.005","article-title":"Esophageal cancer: Risk factors, genetic association, and treatment","volume":"41","author":"Huang","year":"2018","journal-title":"Asian J. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/aje\/kwx221","article-title":"Racial and ethnic disparities in the incidence of esophageal cancer in the United States, 1992\u20132013","volume":"186","author":"Xie","year":"2017","journal-title":"Am. J. Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"830","DOI":"10.14309\/ajg.0000000000002606","article-title":"Racial disparity in esophageal squamous cell carcinoma treatment and survival in the United States","volume":"119","author":"Noureldin","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1007\/s10620-011-1853-1","article-title":"Esophageal carcinoma in African Americans: A five-decade experience","volume":"56","author":"Ashktorab","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"ref_7","first-page":"137","article-title":"The characteristics of oesophageal squamous cell carcinoma: An analysis of 1317 cases in southeastern China","volume":"19","author":"Jiang","year":"2015","journal-title":"Contemp. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/1097-0142(19951001)76:7<1120::AID-CNCR2820760704>3.0.CO;2-W","article-title":"Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma","volume":"76","author":"Quint","year":"1995","journal-title":"Cancer"},{"key":"ref_9","first-page":"717","article-title":"Clinical features and prognostic factors in patients with esophageal cancer with bone metastasis","volume":"19","author":"Imura","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/PAI.0000000000000943","article-title":"Variations of p40 and p63 immunostains in different grades of esophageal squamous cell carcinoma: A potential diagnostic pitfall","volume":"29","author":"Chi","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1177\/1066896920924821","article-title":"Head-to-head comparison of p63 and p40 in non-neuroendocrine carcinomas of the tubal gut","volume":"28","author":"Bakhshwin","year":"2020","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4132\/jptm.2018.08.14","article-title":"p40 immunohistochemistry is an excellent marker in primary lung squamous cell carcinoma","volume":"52","author":"Affandi","year":"2018","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41379-020-0503-6","article-title":"Effect of decalcification protocols on immunohistochemistry and molecular analyses of bone samples","volume":"33","author":"Jourdan","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.14309\/ajg.0000000000001680","article-title":"Diagnosis and management of Barrett\u2019s esophagus: An updated ACG guideline","volume":"117","author":"Shaheen","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e70178","DOI":"10.1002\/hsr2.70178","article-title":"The Prognostic Value of Serum Soluble Programmed Death 1 (sPD-1) and Programmed Death Ligand 1 (sPD-L1) in Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis About Cohort Studies","volume":"7","author":"Yu","year":"2024","journal-title":"Health Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e23510","DOI":"10.1016\/j.heliyon.2023.e23510","article-title":"Advanced esophageal cancer with bone metastases: Prognostic biomarkers and palliative treatment","volume":"10","author":"Yuan","year":"2024","journal-title":"Heliyon"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"105854","DOI":"10.1016\/j.esmoop.2025.105854","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study","volume":"10","author":"Metges","year":"2025","journal-title":"ESMO Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17048","DOI":"10.1038\/nrdp.2017.48","article-title":"Oesophageal cancer","volume":"3","author":"Smyth","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","article-title":"Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020","volume":"134","author":"Cao","year":"2021","journal-title":"Chin. Med. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Bochtler","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Laprovitera, N., Riefolo, M., Ambrosini, E., Klec, C., Pichler, M., and Ferracin, M. (2021). Cancer of unknown primary: Challenges and progress in clinical management. Cancers, 13.","DOI":"10.3390\/cancers13030451"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103662","DOI":"10.1016\/j.esmoop.2024.103662","article-title":"Unfavorable carcinoma of unknown primary with a gastrointestinal profile: A retrospective study","volume":"9","author":"Guidi","year":"2024","journal-title":"ESMO Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e2400041","DOI":"10.1200\/OA-24-00041","article-title":"Cancer of Unknown Primary Site: A New Era of Practice-Changing Approaches to Diagnosis, Staging, and Precision Therapy","volume":"1","author":"Greco","year":"2024","journal-title":"JCO Oncol. Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.21037\/jtd.2017.08.72","article-title":"Patterns of distant organ metastases in esophageal cancer: A population-based study","volume":"9","author":"Ai","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"ref_25","first-page":"848","article-title":"Occult esophageal squamous cell carcinoma presenting with multiple bony osteolytic lesions clinically mimicking multiple myeloma: A diagnostic dilemma","volume":"13","author":"Lyngdoh","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_26","first-page":"9","article-title":"Squamous cell carcinoma of esophagus presenting as bone metastases in five cases","volume":"19","author":"Rezaee","year":"2007","journal-title":"Iran. J. Otorhinolaryngol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.21037\/tcr-21-2104","article-title":"Bone metastasis of esophageal carcinoma diagnosed as a first primary tumor: A population-based study","volume":"11","author":"Wang","year":"2022","journal-title":"Transl. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1136\/gutjnl-2020-321600","article-title":"Global burden of oesophageal and gastric cancer by histology and subsite in 2018","volume":"69","author":"Arnold","year":"2020","journal-title":"Gut"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"62280","DOI":"10.18632\/oncotarget.11409","article-title":"Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence","volume":"7","author":"Ueda","year":"2016","journal-title":"Oncotarget"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/s41467-024-47195-7","article-title":"A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary","volume":"15","author":"Conway","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13148-024-01638-6","article-title":"Tissue of origin prediction for cancer of unknown primary using a targeted methylation sequencing panel","volume":"16","author":"Sun","year":"2024","journal-title":"Clin. Epigenet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.gie.2019.05.012","article-title":"ASGE guideline on screening and surveillance of Barrett\u2019s esophagus","volume":"90","author":"Qumseya","year":"2019","journal-title":"Gastrointest. Endosc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): A global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/16\/2677\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T04:10:23Z","timestamp":1787544623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/16\/2677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":34,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["diagnostics16162677"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16162677","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}